Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) SVP Laurie Keating sold 30,000 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $135.89, for a total value of $4,076,700.00. Following the completion of the transaction, the senior vice president now owns 41,500 shares in the company, valued at approximately $5,639,435. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at $124.57 on Thursday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. Alnylam Pharmaceuticals, Inc. has a 52-week low of $35.98 and a 52-week high of $147.63.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). The business had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The business’s revenue was up 24.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.21) earnings per share. research analysts predict that Alnylam Pharmaceuticals, Inc. will post -5.21 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of ALNY. Teachers Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 9.1% during the first quarter. Teachers Advisors LLC now owns 80,238 shares of the biopharmaceutical company’s stock valued at $4,112,000 after acquiring an additional 6,662 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Alnylam Pharmaceuticals by 1.3% in the first quarter. Dimensional Fund Advisors LP now owns 112,778 shares of the biopharmaceutical company’s stock worth $5,780,000 after buying an additional 1,428 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Alnylam Pharmaceuticals in the first quarter worth $2,619,000. Capstone Asset Management Co. purchased a new stake in Alnylam Pharmaceuticals in the second quarter worth $232,000. Finally, Bank of Montreal Can increased its position in Alnylam Pharmaceuticals by 4.7% in the second quarter. Bank of Montreal Can now owns 9,974 shares of the biopharmaceutical company’s stock worth $796,000 after buying an additional 446 shares during the last quarter. 88.43% of the stock is owned by institutional investors.
Several research analysts have issued reports on ALNY shares. Barclays increased their price target on Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an “equal weight” rating in a report on Thursday, August 10th. Morgan Stanley increased their price target on Alnylam Pharmaceuticals from $46.00 to $50.00 and gave the stock an “equal weight” rating in a report on Thursday, August 10th. Chardan Capital reiterated a “buy” rating and issued a $124.00 price target (down previously from $131.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, August 10th. Stifel Nicolaus reiterated a “buy” rating and issued a $56.00 price target (up previously from $47.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, August 10th. Finally, Credit Suisse Group reiterated a “buy” rating and issued a $96.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, August 11th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and sixteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $121.85.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.